Table 2.
Triple immunomarkers as the first trial panel in RCC subtyping.
| Tumor Subtype | CK7 | CAIX | AMACR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1+ | 2+ | 0 | 1+ | 2+ | 0 | 1+ | 2+ | |
| CCRCC (n = 50) | 10 | 90 | 0 | 0 | 0 | 100 | 4 | 70 | 26 |
| PRCC I (n = 15) | 0 | 6 | 94 | 100 | 0 | 0 | 0 | 7 | 93 |
| PRCC II (n = 35) | 83 | 17 | 0 | 9 | 77 | 14 | 0 | 11 | 89 |
| ChRCC (n = 20) | 0 | 15 | 85 | 100 | 0 | 0 | 65 | 35 | 0 |
| RO (n = 10) | 80 | 20 | 0 | 100 | 0 | 0 | 100 | 0 | 0 |
| CCPRCC (n = 10) | 0 | 0 | 100 | 0 | 0 | 100 | 80 | 20 | 0 |
| MiT RCC (n = 13) | 100 | 0 | 0 | 100 | 0 | 0 | 62 | 38 | 0 |
| CDC (n = 5) | 0 | 0 | 100 | 100 | 0 | 0 | 0 | 40 | 60 |
Negative: 0, focally positive: 1+, diffusely positive: 2+. Each number represents the precentage of the expression of markers. Abbreviations: CK7, cytokeratin 7; AMACR, alpha-methylacyl-CoA racemase; CAIX, carbonic anhydrase IX; CCRCC, clear-cell carcinoma; PRCC, papillary renal cell carcinoma; ChRCC, chromophobe renal cell carcinoma; RO, renal oncocytoma; CCPRCC, clear-cell papillary renal cell carcinoma; MiT RCC: microphthalmos gene translocation-associated renal cell carcinoma; CDC, collecting duct carcinoma.